Company: VRCA
Filing Date: 2025-04-30
Form Type: DEFR14A
Source: 0001193125-25-105562
Chunk: 52

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-04-30
Form: DEFR14A
Chunk 52
---
 installments thereafter, subject to the recipient’s continued service through each vesting date. |

| (6) | The remaining unvested shares of common stock underlying this option vest and become exercisable in 27 equal monthly installments until March 1, 2027, subject to the recipient’s continued service through each vesting date. |

| (7) | The remaining unvested shares of common stock underlying this option vest and become exercisable in 14 equal monthly installments until February 24, 2026, subject to the recipient’s continued service through each vesting date. |

| (8) | The remaining unvested shares of common stock underlying this option vest and become exercisable in 3 equal monthly installments until March 1, 2025, subject to the recipient’s continued service through each vesting date. |

| (9) | These shares represent RSUs granted in March 2024. The RSU will vest in 4 equal annual installments on March 15, 2025, March 15, 2026, March 15, 2027 and March 15, 2028, subject to the holders’ continuous service through each applicable date. |

Narrative to Summary Compensation Table We review compensation annually for all employees, including our executives. In setting executive base salaries and bonuses and granting equity incentive awards, we consider compensation for comparable positions in the market, the historical compensation levels of our executives, individual performance as compared to our expectations and objectives, our desire to motivate our employees to achieve short- and long-term results that are in the best interests of our stockholders, and a long-term commitment to our company. We do not target a specific competitive position or a specific mix of compensation among base salary, bonus or long-term incentives. The Compensation Committee of our Board of Directors has historically determined our executives’ compensation. Our Compensation Committee typically reviews and discusses management’s proposed compensation with the Chief Executive Officer for all executives other than the Chief Executive Officer. Based on those discussions and its discretion, the Compensation Committee then recommends the compensation for each executive officer. Our Compensation Committee, without members of management present, discusses and ultimately approves the compensation of our executive officers. 37

Annual Base Salary We have entered into employment agreements with each of our named executive officers that establish annual base salaries, which are generally determined, approved and reviewed periodically by our Compensation Committee in order to compensate our named executive officers for the satisfactory performance of duties to us. The following table presents the annual base salaries